American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献_第10页

Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances. 变异组织学肾细胞癌：新的生物学认识带来治疗上的进步。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_438642

Nicholas J Salgia, Zeynep B Zengin, Sumanta K Pal, Nazli Dizman

{"title":"Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.","authors":"Nicholas J Salgia, Zeynep B Zengin, Sumanta K Pal, Nazli Dizman","doi":"10.1200/EDBK_438642","DOIUrl":"10.1200/EDBK_438642","url":null,"abstract":"Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining RCC cases are composed of a heterogeneous combination of diverse histopathologic subtypes, each with unique pathogeneses and clinical features. Although the therapeutic approach to both localized and metastatic RCCs has dramatically changed, first with the advent of antiangiogenic targeted therapies and more recently with the approval of immune checkpoint inhibitor (ICI)-based combinations, these advances have primarily benefited the clear cell RCC patient population. As such, there remains critical gaps in the optimization of treatment regimens for patients with non-clear cell, or variant, RCC histologies. Herein, we detail recent advances in understanding the biology of RCC with variant histology and how such findings have guided novel clinical studies investigating precision oncology approaches for these rare subtypes. Among the most common variant histology RCCs are papillary RCC, comprising approximately 15%-20% of all diagnoses. Although a histopathologically diverse subset of tumors, papillary RCC is canonically associated with amplification of the MET protooncogene; recently completed and ongoing trials have investigated MET-directed therapies for this patient population. Finally, we discuss the unique biology of RCC with sarcomatoid dedifferentiation and the recent clinical findings detailing its paradoxical sensitivity to ICIs.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e438642"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Framework for Considering Primary and Subspecialty Palliative Care and Guiding Serious Illness Communication for Patients With Breast Cancer. 考虑乳腺癌患者的初级和亚专业姑息治疗并指导重病沟通的框架。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_432554

Lindsay A Dow, Jennifer Kapo, Frances Boyle, Jennifer A Shin

{"title":"Framework for Considering Primary and Subspecialty Palliative Care and Guiding Serious Illness Communication for Patients With Breast Cancer.","authors":"Lindsay A Dow, Jennifer Kapo, Frances Boyle, Jennifer A Shin","doi":"10.1200/EDBK_432554","DOIUrl":"10.1200/EDBK_432554","url":null,"abstract":"Palliative care is a comprehensive approach aimed at enhancing the quality of life of patients and their families living with serious illnesses such as breast cancer. This approach includes assessing and managing pain and other physical symptoms, attending to psychosocial and spiritual aspects of care, fostering effective communication and decision making, and providing support in coordinating care that upholds a person's values and preferences from the time of diagnosis throughout the illness trajectory. This type of care can be provided by palliative care specialists (ideally an interprofessional team) working alongside the oncology team, referred to as subspecialty palliative care. Conversely, the fundamental aspects of this approach, which we sometimes call primary palliative care, are provided by all clinicians caring for patients with breast cancer. Given that access to subspecialty palliative care can vary globally, especially in rural and resource-constrained settings, it is imperative for all oncology clinicians to receive training in the core components of palliative care. This study aims to provide a basic framework to recognize what the core primary palliative care skills are in routine oncology practice, to delineate basic serious illness communication strategies, and to introduce when to consider the integration of subspecialty palliative care into the care of patients with breast cancer.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e432554"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing Early-Stage Breast Cancer Survivorship: Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines. 加强早期乳腺癌患者的生存能力：以证据为基础的策略、监测测试和成像指南》（Evidence-Based Strategies, Surveillance Testing, and Imaging Guidelines）。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_432564

Mitchell J Elliott, Sherry Shen, Diana L Lam, Thelma Brown, Marissa B Lawson, Neil M Iyengar, David W Cescon

引用次数: 0

Common Sense Oncology: Equity, Value, and Outcomes That Matter. 肿瘤学常识：公平、价值和重要的结果。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_100039

Brooke E Wilson, Manju Sengar, Michelle Tregear, Winette T A van der Graaf, Nicolò Matteo Luca Battisti, Degi Laszlo Csaba, Enrique Soto-Perez-de-Celis, Bishal Gyawali, Christopher M Booth

引用次数: 0

Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. 神经纤维瘤病 1 型相关恶性周围神经鞘瘤的现代治疗方法。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_432242

Angela C Hirbe, Carina A Dehner, Eva Dombi, Vanessa Eulo, Andrea M Gross, Taylor Sundby, Alexander J Lazar, Brigitte C Widemann

引用次数: 0

Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches. 让我们对话：肿瘤学中的重病沟通：定义、障碍和成功方法。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-06-01 DOI: 10.1200/EDBK_431352

Danielle M Shilling, Christopher R Manz, Jacob J Strand, Manali I Patel

{"title":"Let Us Have the Conversation: Serious Illness Communication in Oncology: Definitions, Barriers, and Successful Approaches.","authors":"Danielle M Shilling, Christopher R Manz, Jacob J Strand, Manali I Patel","doi":"10.1200/EDBK_431352","DOIUrl":"10.1200/EDBK_431352","url":null,"abstract":"Serious illness communications are crucial elements of care delivery for patients with cancer. High-quality serious illness communications are composed of open, honest discussions between patients, caregivers, and clinicians regarding patient's communication preferences, expected illness trajectory, prognosis, and risks and benefits of any recommended care. High-quality communication ideally starts at the time of a patients' cancer diagnosis, allows space for and response to patient emotions, elicits patients' values and care preferences, and is iterative and longitudinal. When integrated into cancer care, such communication can result in improved patient experiences with their care, care that matches patients' goals, and reduced care intensity at the end of life. Despite national recommendations for routine integration of these communication into cancer care, a minority of patients with cancer receive such communication. In this chapter, we describe elements of high-quality serious illness communication, patient-, clinician-, institution-, and payer-level barriers, and successful strategies that can routinely integrate such communication into cancer care delivery.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e431352"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors. 针对表皮生长因子受体突变肿瘤的非小细胞肺癌患者的新治疗方案。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_432516

Stephanie P L Saw, Xiuning Le, Lizza E L Hendriks, Jordi Remon

引用次数: 0

Integrating Palliative Care Into the Management of Genitourinary Malignancies. 将姑息治疗融入泌尿生殖系统恶性肿瘤的治疗中。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_438644

Eva K Masel, Joachim Baer, Claudia Wenzel

{"title":"Integrating Palliative Care Into the Management of Genitourinary Malignancies.","authors":"Eva K Masel, Joachim Baer, Claudia Wenzel","doi":"10.1200/EDBK_438644","DOIUrl":"10.1200/EDBK_438644","url":null,"abstract":"Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of patients, provide support to both patients and their caregivers, and help individuals to navigate the complex decisions about treatment and end-of-life care. PC takes a holistic approach to patient care, recognizing that genitourinary malignancies affect multiple aspects of a person's life. By addressing physical, emotional, social, and spiritual needs, PC aims to provide comprehensive support that is consistent with the patient's values and preferences. The goal is to optimize comfort, minimize distress, and enhance the patient's quality of life throughout the course of the illness. PC is not a one-off intervention, but an ongoing source of support. This article aims to provide a thorough overview of the critical elements involved in addressing the challenges posed by genitourinary cancers, emphasizing the importance of palliative interventions. We will highlight the multifaceted aspects of care and explore strategies to optimize the overall well-being of patients throughout the course of treatment for genitourinary malignancies.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e438644"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements and Challenges in the Treatment of AML. 治疗急性髓细胞白血病的进展与挑战。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI: 10.1200/EDBK_438662

Yasmin Abaza, Christine McMahon, Jacqueline S Garcia

{"title":"Advancements and Challenges in the Treatment of AML.","authors":"Yasmin Abaza, Christine McMahon, Jacqueline S Garcia","doi":"10.1200/EDBK_438662","DOIUrl":"10.1200/EDBK_438662","url":null,"abstract":"The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based induction chemotherapy (for all fit patients) or a single-agent hypomethylating agent (in unfit patients or those 75 years and older). While assessing patient fitness remains important, characterizing the disease biology has become critical to select the optimal initial therapy for each patient with more options available. FLT3 inhibitors, gemtuzumab ozogamicin, and CPX-351 have been shown to improve outcomes for specific subsets of patients. Venetoclax (VEN) with a hypomethylating agent (HMA) is the standard-of-care frontline regimen for most older patients, except perhaps for those with an IDH1 mutation where ivosidenib with azacitidine may also be considered. On the basis of the success seen with HMA/VEN in older patients, there is now increasing interest in incorporating VEN into frontline regimens in younger patients, with promising data from multiple early phase studies. This article focuses on recent updates and ongoing challenges in the management of AML, with a particular focus on the ongoing challenge of secondary AML and considerations regarding the selection of initial therapy in younger patients. An overview of common side effects and toxicities associated with targeted therapies is also presented here, along with recommended strategies to mitigate these risks.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e438662"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-Escalation of Therapy for Prostate Cancer. 减轻前列腺癌的治疗。

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-01-01 DOI: 10.1200/EDBK_430466

Tarik Esen, Baris Esen, Kosj Yamaoh, Ugur Selek, Derya Tilki

{"title":"De-Escalation of Therapy for Prostate Cancer.","authors":"Tarik Esen, Baris Esen, Kosj Yamaoh, Ugur Selek, Derya Tilki","doi":"10.1200/EDBK_430466","DOIUrl":"10.1200/EDBK_430466","url":null,"abstract":"Prostate cancer (PCa) is the second most commonly diagnosed cancer in men with around 1.4 million new cases every year. In patients with localized disease, management options include active surveillance (AS), radical prostatectomy (RP; with or without pelvic lymph node dissection), or radiotherapy to the prostate (with or without pelvic irradiation) with or without hormonotherapy. In advanced disease, treatment options include systemic treatment(s) and/or treatment to primary tumour and/or metastasis-directed therapies (MDTs). Specifically, in advanced stage, the current trend is earlier intensification of treatment such as dual or triple combination systemic treatments or adding treatment to primary and MDT to systemic treatment. However, earlier treatment intensification comes with the cost of increased morbidity and mortality resulting from drug-/treatment-related side effects. The main goal is and should be to provide the best possible care and oncologic outcomes with minimum possible side effects. This chapter will explore emerging possibilities to de-escalate treatment in PCa driven by enhanced insights into disease biology and the natural course of PCa such as AS in intermediate-risk disease or salvage versus adjuvant radiotherapy in post-RP patients. Considerations arising from advancements in PCa imaging and technological advancements in surgical and radiation therapy techniques including omitting pelvic lymph node dissection in the era of prostate-specific membrane antigen positron emitting tomography, the potential of MDT to delay/omit systemic treatment in metachronous oligorecurrence, and the efficacy of hypofractionation schemes compared with conventional fractionated radiotherapy will be discussed.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 2","pages":"e430466"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139418260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0